Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
COVID-19 Programs
COVISTIX™ (diagnostic) Rapid Antigen Test 0%* Emergency Use Authorization (EUA) in Mexico (COFEPRIS), Brazil (ANVISA), and CE Marked in Europe COVIMARK™ (diagnostic) Rapid Antigen Test 0%* Application submitted in the US and Canada for Emergency Use Authorization (EUA) VIREX (diagnostic) At Home Diagnostic 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) ARDS due to COVID-19 in ICU Patients 82%* Pivotal Trial in Brazil                           OVYDSO (Olgotrelvir) Anti-viral (Oral Pill) 40%* Omicron mRNA Vaccine Vaccine 20%*
Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
Immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE™ (Abivertinib) Prostate 20%* PD-L1 (Socazolimab)* SCLC 82%* *In Partnership with Lee’s Pharm in China PD-L1 (STI-3031)** Cervical Cancer 82%* **In US and in partnership with ImmuneOncia in Korea CD47 Solid Tumors 40%* CD38 DAR-T Multiple Myeloma 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, and esophageal 40%* TROP2 ADC* Solid Tumors 40%* Seprehvec™ oncolytic virus Solid Tumors; CNS Tumors 40%* BCMA ADC Liquid Tumors 20%* Bevacizumab-ADNAB™ Endometrial Cancer 40%* In partnership with Mayo Clinic Bevacizumab-ADNAB™ Ovarian Cancer 40%* In partnership with Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* In partnership with Mayo Clinic Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%*
Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
Pain
ZTlido® 1.8% Postherpetic Neuralgia - PHN 99.8%* Gloperba® Treatment of Gout (Oral) 99.8%* SEMDEXA (SP-102) Lumbar Radicular/Sciatica Pain 82%* SP-103 (Lidocaine Topical System 5.4%) Acute Back Pain 60.2%* SP-104 (Delayed Burst Low Dose Naltrexone) Fibromyalgia 20%* RTX (resiniferatoxin) Epidural injection Intractable Pain in Advanced Cancer 60.3%* Orphan designation RTX (resiniferatoxin) Intra-articular route Moderate to Severe Knee OA Pain 60.2%*
Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
Lymphatic Drug Delivery
Sofusa® anti-TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%* Sofusa® anti-CTLA-4 Melanoma 40%* In partnership with Mayo Clinic

COVID-19 Programs
Key Programs (Indication)	Phase
COVISTIX™ (diagnostic) FDA EUA COVIMARK™ (diagnostic) FDA EUA VIREX (diagnostic) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III OVYDSO (Olgotrelvir) Ph II Omicron mRNA Vaccine Preclinical

Immunotherapy
Key Programs (Indication)	Phase
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Preclinical PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Solid Tumors) Ph I CD38 DAR-T (Multiple Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, and esophageal) Ph I TROP2 ADC* (Solid Tumors) Ph I Seprehvec™ oncolytic virus (Solid Tumors; CNS Tumors) PH I BCMA ADC (Liquid Tumors) Preclinical Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I

Pain
Key Programs (Indication)	Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval Gloperba® 1.8% Treatment of Gout (Oral) FDA Approval SEMDEXA (SP-102) Ph III SP-103 (Lidocaine Topical System 5.4%) Ph II SP-104 (Delayed Burst Low Dose Naltrexone) Preclinical RTX (resiniferatoxin) Epidural injection Ph II RTX (resiniferatoxin) Intra-articular route Ph II

Lymphatic Delivery
Key Programs (Indication)	Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I Sofusa® anti-CTLA-4 (Melanoma) Ph I